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Abstract
Introduction The Venus p-valve (MedTech, Shanghai,
China) is a self-expanding percutaneous heart valve de-
signed to be implanted in a native patched right ventricle
outflow tract. The worldwide clinical experience with this
valve is just beginning and the results have so far been
encouraging. We present our initial early experience im-
planting the Venus p-valve in the native right ventricle
outflow tract of patients with Tetralogy of Fallot repaired
with a transannular patch.
Methods In 10 selected patients a procedure for percuta-
neous pulmonary valve implantation was performed using
the Venus p-valve. The patients mean age was 32 years
(13–57), mean weight 59.6 kg (40–80). All patients had
Tetralogy of Fallot with moderate to severe pulmonary re-
gurgitation and an indication for pulmonary valve replace-
ment.
Results The implantation procedure was successful in all
the patients resulting in an immediately functional valve.
No procedure-related complications were observed. Fol-
low-up after 12 months (4–21) resulted in an improvement
in NYHA class. There was a reduction of the mean right
ventricle diastolic volume from 139 ml/m2 (105–179) to
78 ml/m2 (65–100) and improvement in the regurgitation
fraction from 42% (29–58) to 1% (0–5), as seen on routine
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cardiac magnetic resonance 6 months after the implantation.
No stent fractures have been observed so far.
Conclusion Percutaneous pulmonary valve implantation
with the Venus p-valve resulted in a safe and effective pro-
cedure. The valve has predictable and sustained functional
competence, resulting in clinical improvement in the pa-
tients.
Keywords Pulmonary regurgitation · Percutaneous
pulmonary valve implantation · Native right ventricle
outflow tract · Venus p-valve
Introduction
Percutaneous pulmonary valve implantation has become
a safe and effective option for patients needing pulmonary
valve replacement after surgical repair [1–3]. The currently
available percutaneous valves (Melody or Sapien) are rec-
ommended to be implanted only in right ventricle outflow
tracts (RVOT) constituted by homografts or conduits. How-
ever, most of the patients with Tetralogy of Fallot undergo
a repair using a transannular patch technique which deter-
mines a dilated and distensible RVOT usually exceeding the
diameter of the available percutaneous valves [4]. For these
reasons there is a need for a valve that can be implanted
in the native RVOT and is large enough for the diameters
usually found in patched RVOT.
The Venus p-valve (Venus MedTech, Shanghai, China)
is a self-expanding percutaneous valve designed to be im-
planted in a native patched RVOT. It has already been tested
[5, 6] with satisfactory and encouraging results but is still
not CE certified or FDA approved. The aim of this study
was to report our initial experience on the feasibility and
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Fig. 1 The Venus p-valve.
Note its particular design with
flared ends, the non-covered dis-
tal end and the proximal hooks
or ‘ears’ for attaching mecha-
nism to the delivery catheter
Fig. 2 The Venus p-valve delivery system. Note the handle with
a knob for slow and controlled release of the valve and the distal cap-
sule with a crimped and loaded valve inside. The arrow signs a distal
radiopaque mark
results of percutaneous implantation of the Venus P-valve
in the pulmonary position in patients with native RVOT.
Materials and methods
Patients
Patients with Tetralogy of Fallot repaired using a transannu-
lar patch technique were considered for percutaneous inser-
tion of a Venus p-valve. Patients were selected based mostly
on cardiac magnetic resonance (MRI) information when
fulfilling two of the following inclusion criteria: moderate
to severe pulmonary regurgitation and pulmonary regurgi-
tant fraction >25%, right ventricular end-diastolic volume
index >150 ml/m2, right ventricular ejection fraction <45%,
NYHA class II or III symptoms and the pulmonary valve
annulus or conduit size of >18 mm and <30 mm. Exclusion
criteria were patients with body weight <30 kg, occluded
central veins, unfavourable RVOT anatomy as aneurysmal
dilation, tortuosity of the main pulmonary artery (MPA) and
a pyramid-shaped RVOT.
All the patients were evaluated with transthoracic
echocardiography to assess: right ventricular size and
function, tricuspid regurgitation, right ventricular systolic
pressure, RVOT gradient and the degree of pulmonary
regurgitation. In particular, a short axis view was used to
measure the diameters of the pulmonary valve annulus,
the MPA and pulmonary artery branches as well the MPA
length, which is particularly useful for selecting the length
of the valve to implant. MRI was also performed to define
the size and the anatomy of the RVOT and pulmonary
artery, left and right ventricular volumes and function and
to calculate the pulmonary regurgitant fraction. With this
information (particularly from echocardiographic measure-
ments) the manufacturing company ensures that three or
four possible valve sizes are available to be used in the
patients on the day of the procedure. The study was ap-
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Fig. 3 Sizing balloon interrogation of the right ventricle outflow
tract in caudal projection (a) and lateral projection (b) with measure-
ments included. Simultaneously selective left coronary angiogram is
observed
proved by the local Institutional Review Board at each
participating institution. Informed consent was obtained
from the patients or parents for all the patients.
Valve and delivery system
The Venus P-valve consists of a self-expanding stent made
of nitinol with a tri-leaflet porcine pericardial tissue valve
preserved in a low-concentration solution of buffered glu-
taraldehyde and hand-sewn inside of the nitinol frame
(Fig. 1). The stent has proximal and distal flares to an-
chor the valve in the RVOT and in the pulmonary artery
bifurcation. The proximal flare is covered by pericardial
tissue, whereas the distal flare is an open cell wire frame
to avoid obstruction of the pulmonary artery branches.
The middle part is also fully covered by pericardium and
the valve. There are three radiopaque platinum markers
at the proximal flare to identify the valve location. The
diameters of the middle part range from 18 to 34 mm with
2 mm increments and the lengths range from 20 to 35 mm
with 5 mm increment. The proximal and distal flare di-
ameters are 10 mm larger than the middle segment. There
are two small hooks at the proximal part of the valve for
attachment to the delivery system (Fig. 1). The delivery
system consists of a 16 Fr 100-cm-long shaft catheter with
a 20–22 Fr capsule and a handle rotating mechanism for
controlled deployment of the valve (Fig. 2). The valved
stent is crimped and loaded onto the delivery system under
sterile cold saline solution which helps to reduce the mem-
ory property of nitinol. The delivery system is advanced
through a 22–24 Fr sheath.
Procedure
All procedures were performed under general anaesthesia
and biplane laboratory was used. Anticoagulation with hep-
arin 100 UI/kg was routinely used at the beginning of the
procedure. Intraprocedural cefazolin 100 mg/kg/day was
given. Following a full basic haemodynamic assessment,
angiograms were performed in the RVOT and MPA in or-
der to characterise the shape and diameter of the RVOT and
pulmonary artery bifurcation. Angiograms were usually
performed in posteroanterior and lateral projections, and
additionally in right anterior oblique with cranial angulation
or left anterior oblique with cranial angulation for a better
visualisation of the pulmonary artery bifurcation, since this
understanding is key for the valve deployment. The coro-
nary artery occlusion test was routinely performed with an
aortic angiogram or selective left coronary angiography si-
multaneously with inflation of a 34 mm Amplatzer sizing
balloon in the MPA to assess the expansibility and diameters
as well as the proximity or compression of the left coronary
artery (Fig. 3) which contraindicates the procedure.
The selection of the valve size and length to implant was
based on the minimum diameter of the pulmonary valve an-
nulus/MPA during the sizing interrogation, selecting a valve
diameter 3–4 mm larger than any waist in the sizing bal-
loon. The valve length was selected to cover but not ex-
ceed the MPA length measured from the pulmonary valve
annulus to the pulmonary artery bifurcation on transtho-
racic echocardiograph. Once the valve was prepared and
loaded into the delivery catheter, it was advanced over an
extra-stiff wire (260-cm, 0.0350 Lunderquist, Cook Medi-
cal) located distal in the left pulmonary artery. The valve
was advanced into the main pulmonary artery observing
the distal radiopaque markers of the valve being positioned
just before the pulmonary artery bifurcation (Fig. 4). Then
a slow and controlled valve deployment is performed by
clockwise rotation of the knob in the handle. Repeated
RVOT angiography is performed during the delivery to en-
sure an optimal position and that the distal end is not jail-
ing any of the pulmonary artery branches. After valve de-
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Fig. 4 Fluoroscopic images demonstrating several steps of the im-
plantation procedure. Basal angiogram in the main pulmonary artery
in LAO and cranial projection to visualise pulmonary artery bifurca-
tion (a), advancing and positioning Venus p-valve delivery system in
the RVOT with the tip advanced into proximal left branch (b), deploy-
ment of the distal end of the valve (c), deployment of the central part
of the valve (d), Venus p-valve completely deployed in an appropriate
position (e) and final angiogram demonstrating a functional valve and
patent pulmonary branches (f)
ployment, evaluation is immediately performed including
haemodynamic assessment, pulmonary artery angiography
and transthoracic echocardiography. Haemostasis could be
achieved by using a figure-of-eight suture, preclosure with
the Abbott Perclose Proglide device or manual compression
according operator preferences.
Statistics
Continuous variables are expressed as means, whereas cat-
egorical variables are presented as numbers. Comparison of
parameters before and after pulmonary valve implantation
was analysed using Wilcoxon’s signed rank test. A p-value
<0.05 was considered to be statistically significant.
Results
Ten patients (7 female) were selected to receive a Venus
p-valve and it was successfully implanted in all of them.
Their mean age was 32 years (range 13–57) and their
mean weight was 59.6 kg (range 40–80) (Table 1). Func-
tional class was NYHA II in 7 patients and NYHA III
in 3 patients. All the patients had a basal cardiac MRI
that showed a pulmonary valve annulus with a median of
22.7 mm (range 18 and 27 mm). The mean pulmonary
regurgitant fraction was 42% (range 29–58%), mean right
ventricular ejection fraction was 50.9% (range 33–81%)
and mean right ventricular end-diastolic volume index
was 139 ml/m2 (range 105–179 ml/m2). The mean MPA
diameter measured by sizing balloon interrogation was
27 mm (range 21–30 mm). The mean length of the MPA
was 28.1 mm ± 6.5 mm (range 21 to 38 mm). The im-
planted valve diameters ranged from 26 to 32 mm, whereas
the selected implanted valve length was 25 mm in 7 and
30 mm in 3 patients. Immediate angiography in the MPA
after valve implantation revealed a competent valve in all
the patients. The mean diastolic pulmonary artery pres-
sure increased from 11.4 to 18.9 mm Hg demonstrating
a functional valve (Table 2). The pressure gradient across
the RVOT decreased from 10.3 mm Hg (range 0–30) to
2.9 mm Hg (range 0–10) after the procedure. The mean
fluoroscopy was 29 min (range 23.7–35). The radiation
dose had a mean dose area product of 19,880 mGy*m2
(range 5317–23,454 mGy*m2) and a mean total air Kerma
of 1598 mGy (range 218–2233 mGy). There were no proce-
dure-related complications and no evidence of paravalvular
leaks in any of the patients on transthoracic echocardio-
gram immediately after the procedure. The large profile of
the delivery system did not result in any obvious vascular
damage, nor did it prevent the advance of the valve through
heart structures.
During a mean follow-up of 12 months (range 4–21)
all the patients have remained in NYHA functional class I.
Transthoracic echocardiography and MRI 6 months after
implantation of the valve showed sustained and significant
reduction of the pulmonary regurgitation in all the patients
(Table 2). In 6 patients with MRI follow-up the median
pulmonary regurgitant fraction was 1% (range 0–5%; sig-
nificant at p  0.05) and the right ventricular end-diastolic
volume index was 78 ml/m2 (range 66–100 ml/m2; signifi-
cant at p  0.05). No stent fracture was demonstrated on
fluoroscopic follow-up at 6 months.
Discussion
The worldwide experience in implanting the Venus p-valve
is just beginning with as yet few published reports. We have
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1 13 59 157 M TOF 28 23 27 35 30 30
2 15 53 151 F TOF 24 23 28 32 26 25
3 13 67 162 F TOF 28 27 30 36 30 30
4 25 52 162 F TOF 28 26 29 22 32 25
5 15 40 165 F TOF 26 25 27 23 30 25
6 50 51 152 F PVS 24 22 26 21 28 25
7 57 80 165 F TOF 25 18 28 27 28 30
8 44 72 168 M TOF 29 23 30 24 32 25
9 39 68 175 M PVS 27 22 21 38 26 25
10 49 54 158 F TOF 20 18 24 23 26 25
– – – – – – – – – – – –
Mean 32 59.6 161.5 – – 25.9 22.7 27 28 – –
TOF Tetralogy of Fallot, PVS pulmonary valve stenosis, MPA main pulmonary artery, RV right ventricle, PA pulmonary artery





























1 5 4 12 15 142 a 44 a
2 8 7 9 16 151 a 29 a
3 9 0 9 12 179 a 58 a
4 11 0 17 18 105 66 30 0
5 15 3 10 20 131 100 41 0
6 5 0 11 14 113 90 33 0
7 15 10 13 37 a a a a
8 5 0 10 18 155 73 58 0
9 30 5 10 14 147 70 49 0
10 0 0 13 25 131 72 39 5
Mean 10.3 2.9 11.4 18.9 139 78* 42 1*
RV right ventricle, PA pulmonary artery, RVDV right ventricle diastolic volume
*p  0.05
adata not available
reproduced the encouraging results reported by Cao and
Prompham in 11 patients with Tetralogy of Fallot repaired
using the transannular patch technique [5, 6]. We report
an additional 10 patients with satisfactory results and have
demonstrated a significant reduction of the right ventricular
end-diastolic volume index and sustainable valve integrity
on follow-up MRI. These results are similar to the early
results with Melody and Sapien systems [1–3].
Before the currently available percutaneous pulmonary
valves (Melody and Sapien) can be used in a native RVOT
it is necessary to first implant a large stent to transform
the native RVOT into a rigid conduit [7, 8]. For a native
RVOT up to 26–27 mm, pre-stenting followed by implan-
tation of any of these valves can be performed during the
same procedure or in a staged approach. Also an RVOT re-
ducer used with a self-expanding valve has been previously
reported to address this problem, but it has not resulted in
any development [9, 10]. The Venus p-valve appears to be
an option to address this scenario. This valve is currently
available up to a maximum diameter of 34 mm, which is
indicated for RVOT up to 30–32 mm. Prompham reported
that 6 of 16 patients with the native RVOT and indication
for pulmonary valve replacement could be selected to re-
ceive a Venus p-valve [6]. Patients were excluded because
of a severely dilated main pulmonary artery or unfavourable
RVOT anatomy, such as short pyramid shaped RVOT. Se-
Neth Heart J (2017) 25:76–81 81
lection of our patients based on MRI and echocardiographic
measurements was effective since all of them underwent
a successful procedure.
During the procedure, the deployment and positioning
of the distal end of the valve must to be very precise so
that it does not excessively protrude into the pulmonary
artery bifurcation. To achieve this, radiopaque marks on
the distal end of the straight part of the valve have to be po-
sitioned just at the pulmonary artery bifurcation. Repeated
RVOT angiograms are used to help with this fine position-
ing. Some of these angiograms can be avoided when using
3DRA guidance and on screen 3D roadmap [11]. Haemody-
namic monitoring is crucial during the deployment because
this is a covered stent and when the valve is half deployed
the blood flow through the RVOT can be compromised re-
sulting in hypotension or bradycardia. The proximal end
of the valve needs to be quickly deployed which results in
a rapid recovery of haemodynamics and rhythm.
Incomplete detachment of the valve has been reported
causing unintentional valve migration into the right ventri-
cle [6]. In order to avoid this, attention must to be paid
to the appearance of the proximal flare in two different
fluoroscopic views checking the release from the proximal
hooks. If one of these is not fully released gentle clock-
wise or counterclockwise rotation of the delivery system
may allow the hooks to detach completely from the deliv-
ery system. Also, as a safety tip, the distal end (‘carrot’)
of the delivery catheter must be pulled back carefully and
under fluoroscopic imaging to rule out the theoretical risk
of engaging the stent with this.
Stent fractures were not seen in our patients. This has
been reported for the Melody valve and pre-stenting has
reduced this [12]. For Venus p-valve implantation, pre-
stenting is not necessary but it is possible that a dilated
non-calcified native RVOT exerts less compression force on
the stent frame avoiding the occurrence of stent fractures.
However, the proximal end of the Venus valve is deployed
in the contractile RVOT, this being a factor to produce stent
fractures. Follow-up studies will be needed to evaluate the
occurrence of late fractures.
Conclusions
Our experience reproduces the encouraging initial results
of implanting the Venus p-valve in patients with Tetralogy
of Fallot repaired using the transannular patch technique.
The Venus p-valve is expanding the scope of percutaneous
valve implantation in patients with a dilated RVOT which
is out of range for the available percutaneous valves. The
Venus p-valve seems to work well in the short term follow-
up. Further long-term studies are needed to bring more
information on issues like durability and fractures.
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